Who is sponsoring NCT05794815?

NCT05794815 is sponsored by Min-Tze LIONG.

What drugs are being tested in NCT05794815?

Interventions in NCT05794815: Probiotic, Placebo.

What condition does NCT05794815 study?

NCT05794815 studies Respiratory Infection (for Example, Pneumonia, Bronchitis).

Is NCT05794815 still recruiting?

NCT05794815 is currently recruiting now. Last updated 22 August 2023.

Last reviewed 2023-08-22 · How we verify

NCT05794815

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Modulation of Gut Microbiota by Probiotic in Children With Respiratory Symptoms

Recruiting now NA Last updated 22 August 2023

What this trial tests

NA trial testing Probiotic in Respiratory Infection (for Example, Pneumonia, Bronchitis) in 120 participants. Currently enrolling.

Timeline

1 May 2023

Primary endpoint
1 May 2026

1 May 2026

Quick facts

Lead sponsor	Min-Tze LIONG
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	120
Start date	1 May 2023
Primary completion	1 May 2026
Estimated completion	1 May 2026
Sites	1 location across Malaysia

Drugs / interventions tested

Probiotic
Placebo

Conditions studied

Respiratory Infection (for Example, Pneumonia, Bronchitis) — all drugs for Respiratory Infection (for Example, Pneumonia, Bronchitis) →

Sponsor

Min-Tze LIONG

Who can join

Adults 12 Months to 7, any sex, with Respiratory Infection (for Example, Pneumonia, Bronchitis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project aims to study the benefits of probiotics namely Bifidobacterium infantis YLGB-1496 in modulating gut microbiota of children with respiratory symptoms, among pre-school children in Malaysia aged \>12 months old, \<7 years old.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and Tolerance of Bifidobacterium longum subsp. Infantis YLGB-1496 in Toddlers with Respiratory Symptoms.
Li P, Uma Mageswary M, Taib F, Koo TH, et al · · 2025 · cited 2× · PMID 40647232 · DOI 10.3390/nu17132127
Clinical effects of Bifidobacterium Longum Subsp. Infantis YLGB-1496 on children with respiratory symptoms.
Li P, Mageswary U, Ali A, Taib F, et al · · 2025 · cited 2× · PMID 40046755 · DOI 10.3389/fnut.2025.1537610
Clinical benefits of Bifidobacterium infantis YLGB-1496 in modulating gut microbiota and immunity in young children.
Uma Mageswary M, Li P, Richmond RV, Azianey Y, et al · · 2025 · cited 1× · PMID 41561177 · DOI 10.3389/fnut.2025.1713135
Probiotic improves respiratory and gastrointestinal health, immune homeostasis, and gut microbiota composition in infants: a randomized controlled trial.
Uma Mageswary M, Hanglian L, Li P, Richmond RV, et al · · 2026 · PMID 41878569 · DOI 10.3389/fnut.2026.1746679

Verify or expand the search:

Other trials of Probiotic

Trials testing the same drug.

NCT07529457 — Akk09 in Adults With Constipation · NA · not yet recruiting
NCT07507955 — Probiotics for Constipation Relief in Adults · NA · not yet recruiting
NCT07462481 — Probiotic Improve Constipation · NA · recruiting
NCT07511855 — Stress-buffering and Sleep Disturbance-resilient Effects of a Dual Bifidobacterium Longum Combination Under Short-term T · Phase 2 · not yet recruiting
NCT07474064 — Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC · Phase 2 · not yet recruiting

Other recruiting trials for Respiratory Infection (for Example, Pneumonia, Bronchitis)

Currently open trials in the same condition.

NCT07334795 — Intermountain Stewardship in Community Outpatient Settings-Resources & Engagement-Pediatrics · active not recruiting

Other Min-Tze LIONG trials

Trials by the same sponsor.

NCT07511855 — Stress-buffering and Sleep Disturbance-resilient Effects of a Dual Bifidobacterium Longum Combination Under Short-term T · Phase 2 · not yet recruiting
NCT07384260 — The Effect of Probiotics on Gut Microbiota Changes in Healthy Chinese Adults During Short-Term European Travel: A Random · Phase 2 · not yet recruiting
NCT07498127 — Effects of Probiotics on Respiratory Tract Infections in Children: A Randomized, Placebo-Controlled Interventional Study · Phase 2 · enrolling by invitation
NCT07378852 — Integrated Study on Gut Microbiota, Immune Indicators, and Trace Elements in Children With Respiratory Tract Infections · not yet recruiting
NCT07297966 — Evaluation of the Clinical Efficacy of Antrrix Probiotics in Improving Recurrent Respiratory Infections in Infants and Y · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05794815 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Min-Tze LIONG
Last refreshed: 22 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05794815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing